MedCompanion

Vibrio vulnificus

V. vulnificus

Morphology: Gram-negative curved rod (comma-shaped), oxidase-positive, halophilic. Grows on TCBS agar (green colonies, unlike V. cholerae which is yellow).

GramNegOther

Typical drugs

  1. #1Doxycycline**100 mg PO/IV BID + ceftriaxone** — IDSA preferred combination for V. vulnificus necrotizing infection.
  2. #2Ceftriaxone**1–2 g IV daily** — combine with doxycycline. Active against Vibrio.
  3. #3CiprofloxacinAlternative to doxycycline. Monotherapy with cipro acceptable for milder disease in some guidelines.
  4. #4MeropenemSevere disease or unclear etiology — covers Vibrio + other GNR + anaerobes.

Empiric therapy when resistant

Treatment failure rare with doxycycline + ceftriaxone if started promptly. Surgical debridement is the cornerstone — antibiotics alone fail in established necrotizing disease.

Resistance mechanisms

  • intrinsic

    Variable resistance to ampicillin and 1st-generation cephalosporins

    Example: Empirics should use ceftriaxone-grade or doxycycline, not amp-sulbactam.

Resistance notes

Resistance to first-line agents (doxy, cefotaxime, ceftriaxone, FQ) is rare.

Common syndromes

Pearls

The classic boards vignette: cirrhotic / hemochromatosis / immunocompromised patient eats raw oysters or wades in warm salt water → rapid-onset cellulitis with hemorrhagic bullae → necrotizing fasciitis + septic shock. Mortality 30–50%, even higher if treatment delayed >24 h. Iron overload + immunosuppression are key risk factors. Doxycycline + ceftriaxone + emergent surgical debridement. Aeromonas hydrophila is the freshwater counterpart — similar presentation in freshwater exposure with similar empiric coverage. Notifiable disease.

References